



MATERIAL SAFETY DATA SHEET

Product Name: Furosemide Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

**Manufacturer Name
And Address** Hospira, Inc.
275 North Field Drive
Lake Forest, Illinois 60045
USA

**Emergency Telephone
Hospira, Inc.** CHEMTREC: 800 424-9300
224 212-2055

Product Name Furosemide Injection, USP

Synonyms None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Furosemide
Chemical Formula $C_{12}H_{11}ClN_2O_5S$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Furosemide	1	54-31-9	CB2625000
Water	99	7732-18-5	ZC0110000

3. HAZARD INFORMATION

Emergency Overview In clinical use, this material is used to promote urination. Possible target organs include the kidneys, fetus, DNA and ears.

Occupational Exposure Potential Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms No signs or symptoms from occupational exposure are known. Clinical data suggest the following: electrolyte imbalances, dry mouth, weakness, lethargy, drowsiness, restlessness, muscle pain, muscle weakness, decreased blood pressure, fast heart rate, nausea, vomiting, ringing in the ear, dizziness, headaches.

Medical Conditions Aggravated by Exposure Hypersensitivity to the material and/or similar materials. Pre-existing ailments in the following organs: kidney, ears, liver.

Product Name: Furosemide Injection, USP

4. FIRST AID MEASURES

Eye Contact:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
Ingestion:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability:	Non-flammable
Fire & Explosion Hazard:	None
Extinguishing Media:	Use extinguishing media appropriate for primary cause of fire.
Special Fire Fighting Procedures	No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal	Absorb with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.
-----------------------------------	---

7. HANDLING AND STORAGE

Handling	Protect from light by retaining in carton until contents have been used.
Storage	No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).
Special Precautions	Protect from freezing, light and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Exposure limits		
	OSHA-PEL	ACGIH-TLV	Hospira EEL
Furosemide	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: 100 mcg/m ³ STEL: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Product Name: Furosemide Injection, USP

Respiratory Protection	Respiratory protection is not needed during normal product use.
Skin Protection	If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.
Eye Protection	Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.
Engineering Controls	Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Clear liquid
Odor	Not Determined
Boiling Point	Approximately that of water (100 °C, 212 °F).
Freezing Point	Approximately that of water (0 °C, 32 °F).
Vapor Pressure	Approximately that of water (17.5 mm Hg at 20 °C).
Vapor Density (Air=1)	Not Applicable
Evaporation Rate	Not Applicable
Bulk Density	Not Determined
Specific Gravity	Approximately that of water (1.0)
Solubility	Aqueous solution
pH	8.0 – 9.3

10. STABILITY AND REACTIVITY

Chemical Stability	Stable under standard use and storage conditions.
Incompatibilities	Acids
Hazardous Decomposition Products	Toxic fumes of Cl, sulfur and nitrogen oxides.
Hazardous Polymerization	Not Determined.

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity – Oral:

Ingredient(s)	Percent	Test Type	Value	Units	Species
Furosemide	100	LD50	800-4600	mg/kg	Rabbits, Dogs, Mice, Rats

LD50 is the dosage producing 50% mortality.
Product contains approximately 1% Furosemide.

Mutagenicity	Positive in the mouse lymphoma and chromosomal aberration assays.
Target Organ Effects	In clinical use target organ effects include kidney, fetus, ears, DNA.

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity	Not Available
-------------------------	---------------

Product Name: Furosemide Injection, USP

13. DISPOSAL CONSIDERATIONS:

Waste Disposal Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status Not Regulated

CERCLA Status Not Regulated

SARA Status Not Regulated

RCRA Status Not Regulated

PROP 65 (Calif.) Not Regulated

Notes: TSCA Toxic Substance Control Act
CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA Superfund Amendments and Reauthorization Act
RCRA US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator Global Occupational Toxicology

Date Prepared September 15, 2005

Date Revised October 21, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.